Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
/ 242 items
#XY Event-Driven Stocks↓
FDA Gives Green Light to CardiAMP Heart Cell Therapy for Heart Failure
FDA confirms BioCardia’s CardiAMP Heart Failure II trial may support Premarket Approval for ischemic heart failure.
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.
Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.
Alnylam Teams Up with ChatGPT Creator’s AI Company to Revolutionize RNAi Therapeutics
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.